Various spectators of the bio-tech market have given mixed reviews on Celanese Corporation (CE). Pundit Jim Cramer has expressed his disappointment with the company's performance. However, reports suggest that the stock may be undervalued by 45%. Despite ending the year with $10.3 billion, the company's Q1 earnings call was eagerly awaited. Concerns have been raised over the company's massive $2.6 billion debt restructuring, with speculations on whether this indicates financial strength. The company's stock has seen significant fluctuations, with a major price hike in VAM product pricing, yet nearing an oversold status in the S&P 500. Legal investigations into the company have been launched and shareholders have been urged to learn more. Despite this, institutional owners still favor the company, holding 89% of the stock. However, there has been a notable dividend cut in 2024 and there is anticipation of more to follow. Latest reports show the company's earnings and revenues surpassing estimates in Q4, but there is ongoing concern about weak demand and a substantial dividend reduction.
Celanese Corporation CE News Analytics from Thu, 17 Oct 2024 07:00:00 GMT to Fri, 04 Apr 2025 15:16:14 GMT -
Rating -3
- Innovation -1
- Information -2
- Rumor -4
